AURX

Serial Number 87235356
Registration 5413895
701

Registration Progress

Application Filed
Nov 14, 2016
Under Examination
Oct 10, 2017
Approved for Publication
Aug 15, 2017
Published for Opposition
Aug 15, 2017
Registered
Feb 27, 2018

Trademark Image

AURX

Basic Information

Serial Number
87235356
Registration Number
5413895
Filing Date
November 14, 2016
Registration Date
February 27, 2018
Published for Opposition
August 15, 2017
Drawing Code
4

Status Summary

Current Status
Active
Status Code
701
Status Date
Dec 19, 2024
Registration
Registered
Classes
005

Rights Holder

Tesseract Medical Research, LLC

16
Address
1370 Trancas Street, Suite 350
Napa, CA 94558

Ownership History

Tesseract Medical Research, LLC

Original Applicant
16
Napa, CA

Tesseract Medical Research, LLC

Owner at Publication
16
Napa, CA

Tesseract Medical Research, LLC

Original Registrant
16
Napa, CA

Legal Representation

Attorney
Kim R. Pearson

USPTO Deadlines

Next Deadline
842 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-02-27)
Due Date
February 27, 2028
Grace Period Ends
August 27, 2028

Application History

37 events
Date Code Type Description Documents
Dec 19, 2024 NAS8 E NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED Loading...
Dec 19, 2024 8.OK O REGISTERED - SEC. 8 (6-YR) ACCEPTED Loading...
Dec 18, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Apr 2, 2024 ES8R I TEAS SECTION 8 RECEIVED Loading...
Feb 27, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Feb 27, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 20, 2018 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jan 19, 2018 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jan 13, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jan 12, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 27, 2017 IUAF S USE AMENDMENT FILED Loading...
Dec 27, 2017 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Oct 10, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 15, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 15, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 26, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 11, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 11, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 11, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 11, 2017 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jul 11, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jun 27, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 26, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 26, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 6, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 6, 2017 GNRT O NON-FINAL ACTION E-MAILED Loading...
May 6, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 20, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 20, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 13, 2017 ALIE A ASSIGNED TO LIE Loading...
Mar 30, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 21, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 21, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 21, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 21, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 18, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 17, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Dietary supplements; nutritional supplements; medical foods, namely, medical food supplements and dietetic food supplements, both containing short-chain fatty acids in single molecule form with a release agent that enhances solubility and absorption; nutritional ingredients, namely, a blend of nutrients, namely, short-chain fatty acids in single molecule form with a release agent that ensures solubility and absorption, that are an integral component of medicals foods, for short-chain fatty acid deficiencies in individuals with Autism Spectrum Disorder; nutraceuticals for use as dietary supplements and nutritional supplements; vitamin preparations and mineral preparations to mitigate short-chain fatty acid microbiome deficiencies in individuals with Autism Spectrum Disorder; dietary supplements for restoring health in individuals with diseases, disorders, nutritional deficiencies, and adverse health conditions; therapeutic agents for human medical, medicinal, and therapeutic purposes, namely, increasing butyric acid and acetic acid in the gastrointestinal tract; functional nutrients containing butyric acid and acetic acid to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; pharmaceutical preparations to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; specialty nutraceuticals for the dietary management of diseases, disorders, and nutritional deficiencies, namely, short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder and deficiencies of butyrate in the gastrointestinal tract
First Use Anywhere: Jul 17, 2017
First Use in Commerce: Jul 17, 2017

Classification

International Classes
005